BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FivePrime Therapeutics, Inc. and Fast Forward, LLC Collaborate to Speed New Treatments to People With Multiple Sclerosis


5/25/2010 8:59:22 AM

SAN FRANCISCO--(BUSINESS WIRE)--Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.

Under the terms of the agreement Fast Forward will provide funds to enable pre-clinical testing of a proprietary and innovative biological molecule discovered at FivePrime. This biologic targets specific cells of the innate immune system, a mechanism that differentiates this potential therapy from the approved treatments for MS. The innate immune system is a component of the body’s immune system and recent research has suggested that it contributes to disease activity in both relapsing remitting and progressive forms of MS.

“We are delighted to be able to work with Fast Forward in order to bring new treatments to people with MS. MS is an important area of innovation and focus at FivePrime,” said Brian Wong, MD, PhD, vice president, immunology and discovery research at FivePrime. “Fast Forward’s support provides important validation of FivePrime’s powerful discovery engine and the company’s growing pipeline of first-in-class therapeutic biologics."

“We are pleased to partner with FivePrime to accelerate the development of new treatments for people with MS. Their high-caliber scientists have identified a new treatment strategy which should be explored further,” adds Dr. Timothy Coetzee, president of Fast Forward. “Five Prime’s approach fits well with our strategy of supporting innovative and promising new treatments for MS.”

About MS

MS is a chronic, unpredictable neurological disease that affects the central nervous system. It is thought to be an autoimmune disorder, meaning the immune system incorrectly attacks healthy tissue. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. These problems may be permanent or may come and go.

About FivePrime

Five Prime Therapeutics, Inc. is a clinical-stage, privately-held company discovering and developing innovative protein and antibody therapeutics. FivePrime is currently in Phase I with FP-1039 for solid tumors. Using its world-class biologics discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. It has built a unique suite of technologies to selectively mine the entire extracellular human proteome – the complete collection of secreted proteins and receptors - for medically relevant therapeutic protein drugs. FivePrime is collaborating with Pfizer, Inc. in the fields of oncology and diabetes. For more information, visit www.fiveprime.com.

About Fast Forward, LLC

Fast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS. Fast Forward will accomplish its mission by connecting university-based MS research with private-sector drug development and by funding small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS.

www.fastforward.org

About The National Multiple Sclerosis Society

The National MS Society addresses the challenges of each person affected by MS by funding cutting-edge research, driving change through advocacy, facilitating professional education, collaborating with MS organizations around the world, and providing programs and services designed to help people with MS and their families move their lives forward. We are people who want to do something about MS now, and are dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org.

Contacts
Five Prime Therapeutics, Inc.
Stephanie Andrade, 415-365-5719
stephanie.andrade@fiveprime.com
or
Fast Forward, LLC
Arney Rosenblat, 212-476-0436
Arney.Rosenblat@nmss.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES